What Stereotaxis (STXS) Said on Its Q3 Earnings Call

Impact · against what's priced in

STXS secures a critical liquidity bridge to reach its 2027 profitability goal, though significant supply chain failures with Osypka create a ceiling on immediate revenue realization. The $12M financing extends the runway, but the inability to convert $1.9M in disposable orders into revenue highlights a dangerous dependence on a single manufacturer.

STXS+0.30

No priced-in read yet

In context

The company significantly extended its runway by increasing pro forma cash from $4 million to $16 million via a convertible note, though this is partially offset by $1.9 million in backlog that cannot be realized due to MAGiC catheter shortages.

Read from the article alone

• earnings
• JNJ
• STXS
• convertible note
• fda clearance
• financing
• healthcare equipment
• medtech
• profitability outlook
• robotic surgery
• supply chain